{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T12:24:11Z","timestamp":1709727851264},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,12,15]]},"DOI":"10.2169\/internalmedicine.4731-20","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T22:09:46Z","timestamp":1597183786000},"page":"3187-3193","source":"Crossref","is-referenced-by-count":2,"title":["Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission"],"prefix":"10.2169","volume":"59","author":[{"given":"Reiko","family":"Muto","sequence":"first","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"},{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokazu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Sameshima","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hamamatsu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nagakura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hamamatsu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hamamatsu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Akahori","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 12: 1680-1691, 2017.","DOI":"10.2215\/CJN.02500317"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12: 570-579, 2016.","DOI":"10.1038\/nrrheum.2016.123"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66: 222-227, 2007.","DOI":"10.1136\/ard.2006.054593"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takagi H, Hagirawa D, Handa T, et al. Diagnosis of central diabetes insipidus using a vasopressin radioimmunoassay during hypertonic saline infusion. Endocr J 67: 267-274, 2020.","DOI":"10.1507\/endocrj.EJ19-0224"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Travis WD, Hoffman GS, Leavitt RY, et al. Lung in Wegener&apos;s Granulomatosis. Am J Surg Pathol 15: 315-333, 1991.","DOI":"10.1097\/00000478-199104000-00001"},{"key":"6","unstructured":"6. Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 26: 537-542, 2015."},{"key":"7","unstructured":"7. Yamaguchi M, Ando M, Kato S, et al. Increase of antimyeloperoxidase antineutrophil cytoplasmic antibody (ANCA) in patients with renal ANCA-associated vasculitis: association with risk to relapse. J Rheumatol 42: 1853-1860, 2015."},{"key":"8","unstructured":"8. Watanabe H, Sada KE, Matsumoto Y, et al. Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol 70: 1626-1633, 2018."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol 5: 313-318, 2009.","DOI":"10.1038\/nrneph.2009.67"},{"key":"10","unstructured":"10. Outh R, Lemaire A, Mania A, Berland P, et al. Relapse in patients with anti-neutorphil cytoplasmic antibody-associated vasculitis: a retrospective study. Clin Rheumatol. Forthcoming."},{"key":"11","unstructured":"11. Kapoor E, Cartin-Ceba R, Specks U, Leavitt J, Erickson B, Erickson D. Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience. J Clin Endocrinol Metab 99: 3988-3994, 2014."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Yong TY, Li JY, Amato L, et al. Pituitary involvement in Wegener&apos;s granulomatosis. Pituitary 11: 77-84, 2008.","DOI":"10.1007\/s11102-007-0021-2"},{"key":"13","unstructured":"13. De Parisot A, Puechal X, Langrand C, et al. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore) 94: e748, 2015."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Holle JU, Gross WL. Neurological involvement in Wegener&apos;s granulomatosis. Curr Opin Rheumatol 23: 7-11, 2011.","DOI":"10.1097\/BOR.0b013e32834115f9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Esposito D, Trimpou P, Giugliano D, Dehlin M, Ragnarsson O. Pituitary dysfunction in granulomatosis with polyangiitis. Pituitary 20: 594-601, 2017.","DOI":"10.1007\/s11102-017-0811-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Vega-Beyhart A, Medina-Rangel IR, Hinojosa-Azaola A, et al. Pituitary dysfunction in granulomatosis with polyangiitis. Clin Rheumatol 39: 595-606, 2020.","DOI":"10.1007\/s10067-019-04735-7"},{"key":"17","unstructured":"17. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488-498, 1992."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener&apos;s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842-852, 1998.","DOI":"10.1681\/ASN.V95842"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener&apos;s granulomatosis. Int J Cancer 100: 82-85, 2002.","DOI":"10.1002\/ijc.10444"},{"key":"20","unstructured":"20. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener&apos;s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100-105, 2008."},{"key":"21","unstructured":"21. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 70: 1415-1421, 2011."},{"key":"22","unstructured":"22. Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener&apos;s): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 63: 2495-2503, 2011."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rahmattulla C, Berden AE, Wakker SC, et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol 67: 3270-3278, 2015.","DOI":"10.1002\/art.39317"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 54: 1345-1350, 2015.","DOI":"10.1093\/rheumatology\/keu372"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener&apos;s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836-2840, 2001.","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W"},{"key":"26","unstructured":"26. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener&apos;s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173: 180-187, 2006."},{"key":"27","unstructured":"27. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74: 1178-1182, 2015."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369: 417-427, 2013.","DOI":"10.1056\/NEJMoa1213277"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.","DOI":"10.1056\/NEJMc1009101"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Karassa FB. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 2073, 2010.","DOI":"10.1056\/NEJMc1009101"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 363: 285-286, 2010.","DOI":"10.1056\/NEJMe1004992"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 76: 1064-1069, 2017.","DOI":"10.1136\/annrheumdis-2016-209925"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/24\/59_4731-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T15:35:32Z","timestamp":1667748932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/24\/59_4731-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4731-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}